Zivo Bioscience Form 4: 926 options granted at $12.03

Zivo Bioscience (ZIVO) reported an insider equity award.

Rhea-AI Filing Summary

Zivo Bioscience (ZIVO) reported an insider equity award. On 10/02/2025, a reporting person who is a Director and 10% Owner received 926 nonstatutory stock options to buy common stock at an exercise price of $12.03 per share, expiring on 10/02/2035. The filing notes the option grant was issued under the 2024 Equity Incentive Plan for Non-Employee Directors in lieu of retainer fees totaling $9,452.05. Ownership of these derivative securities is listed as Direct (D).

Insider Trade Summary

Grant/Award: 926 shares

Grant/Award 1 txn

Insider YALDOO LAITH L

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Nonstatutory Stock Options to buy Common Stock	926	$10.20	$9K

Holdings After Transaction: Nonstatutory Stock Options to buy Common Stock — 926 contracts (Direct)

Footnotes (1)

1. F1. This option was issued to the reporting person pursuant to the 2024 Equity Incentive Plan for Non-Employee Directors in lieu of retainer fees of $9,452.05.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ZIVO disclose in this Form 4?

A Director and 10% Owner was granted 926 nonstatutory stock options on 10/02/2025 with a $12.03 exercise price and 10/02/2035 expiration.

What plan governs the reported ZIVO option grant?

The options were issued under the 2024 Equity Incentive Plan for Non-Employee Directors.

Was the grant tied to director fees at ZIVO (ZIVO)?

Yes. The filing states the options were issued in lieu of retainer fees totaling $9,452.05.

How many ZIVO shares are underlying the options?

The options are exercisable for 926 shares of Zivo Bioscience common stock.

What is the ownership form of the reported derivative securities?

The filing lists the ownership form as Direct (D).

What is the price of the derivative security noted in the filing?

The filing lists a derivative security price of $10.2, with an accompanying footnote referencing the fee-in-lieu grant.

Who signed the ZIVO Form 4 and when?

The form was signed by /s/ Laith L. Yaldoo on 10/06/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/06/2025 - 08:36 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

YALDOO LAITH L

(Last) (First) (Middle)

2125 BUTTERFIELD ROAD

SUITE 100

(Street)

TROY MI 480984

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zivo Bioscience, Inc. [ ZIVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Nonstatutory Stock Options to buy Common Stock	$12.03	10/02/2025		A		926		10/02/2025	10/02/2035	Common Stock	926	$10.2(1)	926	D

Explanation of Responses:

1. This option was issued to the reporting person pursuant to the 2024 Equity Incentive Plan for Non-Employee Directors in lieu of retainer fees of $9,452.05.

	/s/ Laith L. Yaldoo	10/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.